APA (7th ed.) Citation

CG, M., DI, C., N, D., BJ, A., KR, M., K, T., . . . AT, F. (2026). Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. British journal of haematology. https://doi.org/10.1111/bjh.70671

Chicago Style (17th ed.) Citation

CG, Moore, et al. "Clinical Outcomes of Combination Treatment with FMS-like Tyrosine Kinase 3 (FLT3) and Isocitrate Dehydrogenase 1/2 (IDH1/2) Inhibitors in Patients with Acute Myeloid Leukaemia." British Journal of Haematology 2026. https://doi.org/10.1111/bjh.70671.

MLA (9th ed.) Citation

CG, Moore, et al. "Clinical Outcomes of Combination Treatment with FMS-like Tyrosine Kinase 3 (FLT3) and Isocitrate Dehydrogenase 1/2 (IDH1/2) Inhibitors in Patients with Acute Myeloid Leukaemia." British Journal of Haematology, 2026, https://doi.org/10.1111/bjh.70671.